Loading...
Diagnostic accuracy of serum pepsinogens for detecting chronic atrophic gastritis and gastric cancer: A meta-analysis
Зохиогч
Ganchimeg Dondov
Batbold Batsaikhan
Tegshjargal Badamjav
Sodnomtsogt Lkhagvasuren
Tulgaa Lonjid
Он
2026 оны долоодугаар сарын 7
Төрөл
review article
Journal
Eurasian Journal of Medicine and Oncology
Volume
0
Issue
0
Start Page
026110126
End Page
026110126
ISSN
2587-196X
2587-2400
Хураангуй
Introduction: Recent studies have shown that serological biomarkers such as pepsinogens may facilitate the early detection of gastric cancer. Objective: This study aims to evaluate the diagnostic performance of serum pepsinogen I (PGI) and the PGI/pepsinogen II ratio (PGR) in detecting gastric cancer and chronic atrophic gastritis. Methods: A systematic literature search was conducted using MeSH terms related to atrophic gastritis, gastric neoplasms, pepsinogen A, sensitivity, and specificity. Twenty-one eligible studies were included in the quantitative synthesis. Results: For atrophic gastritis, the area under the curve was 0.74 (95% confidence interval [CI] = 0.70–0.77) for PGI and 0.78 (95% CI = 0.75–0.82) for PGR. The pooled sensitivity and specificity were 61.4% (95% CI = 48.2–73.2) and 86.4% (95% CI = 61.8–96.1), respectively, for PGI, and 72.4% (95% CI = 61.0–81.4) and 76.9% (95% CI = 49.5–91.9), respectively, for PGR. For gastric cancer detection, the area under the curve values were 0.76 (95% CI = 0.72–0.80) for PGI, 0.77 (95% CI = 0.73–0.80) for PGR, and 0.79 (95% CI = 0.75–0.83) for the combined PGI+PGR model. The pooled sensitivity and specificity were 69.8% (95% CI = 55.0–81.3) and 70.8% (95% CI = 58.7–80.6), respectively, for PGI, 76.2% (95% CI = 65.4–84.2) and 66.1% (95% CI = 56.1–74.8), respectively, for PGR, and 61.5% (95% CI = 50.9–72.1) and 86.7% (95% CI = 79.4–94.1), respectively, for PGI+PGR. Conclusion: Serum PGI and PGR can be used as an additional screening for high-risk subjects who may require gastroscopy or biopsy.